David Fuller
Chief Tech/Sci/R&D Officer bei DIMERIX LIMITED
Vermögen: 1 759 $ am 31.03.2024
Profil
David Fuller is currently the Chairman of EpiAxis Therapeutics Pty Ltd.
He also holds the position of Non-Executive Director at AdAlta Ltd.
since 2020 and will be the Chief Medical Officer at Dimerix Ltd.
starting in 2023.
Previously, he was the Chief Medical Officer at Race Oncology Ltd.
from 2021 to 2022.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
RACE ONCOLOGY LTD.
0,00% | 30.06.2023 | 1 899 ( 0,00% ) | 1 759 $ | 31.03.2024 |
Aktive Positionen von David Fuller
| Unternehmen | Position | Beginn |
|---|---|---|
| ADALTA LIMITED | Director/Board Member | 22.07.2020 |
| DIMERIX LIMITED | Chief Tech/Sci/R&D Officer | 23.10.2023 |
EpiAxis Therapeutics Pty Ltd.
 EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Chairman | - |
Ehemalige bekannte Positionen von David Fuller
| Unternehmen | Position | Ende |
|---|---|---|
| RACE ONCOLOGY LIMITED | Chief Tech/Sci/R&D Officer | 11.11.2022 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| DIMERIX LIMITED | Health Technology |
| ADALTA LIMITED | Health Technology |
| RACE ONCOLOGY LIMITED | Health Technology |
| Private Unternehmen | 1 |
|---|---|
EpiAxis Therapeutics Pty Ltd.
EpiAxis Therapeutics Pty Ltd. BiotechnologyHealth Technology EpiAxis Therapeutics Pty Ltd. engages in biotechnology company. It pursuing a preclinical and clinical drug development program directed at the prevention of metastatic disease by targeting the pivotal enzyme system controlling the proliferation of cancer stem cells. The company was founded by Jeremy Chrisp and Sudha Rao and is headquartered in Canberra, Australia. | Health Technology |
